Investigation of Finerenone Treatment Effects and Safety

Retrospective Observational Study on the Effectiveness and Safety of Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease - Finerenone Retrospective Observational Study in T2DM with CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057999

Enrollment

100

Registered

2025-07-30

Start date

2025-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated at Meitetsu Hospital Aged 18 years or older Diagnosed with type 2 diabetes and chronic kidney disease and initiated on finerenone Able to be followed for at least 3 months Opt-out consent has been appropriately obtained

Exclusion criteria

Exclusion criteria: Patients with end-stage renal disease (on dialysis or eGFR <15 mL/min/1.73m) Patients who discontinued finerenone within one month after initiation Patients deemed inappropriate for inclusion by the attending physician

Design outcomes

Primary

Measure	Time frame
The primary outcome is the change in estimated glomerular filtration rate (eGFR) at 3 months and 6 months after the initiation of treatment.	—

Secondary

Measure	Time frame
Secondary outcomes include changes in urinary albumin-to-creatinine ratio, serum potassium levels, urinary sodium excretion, and blood pressure after treatment initiation.	—

Countries

Japan

Contacts

Public ContactSaori Inoue

Meitetsu Hospital Department of Endocrinology and Metabolism

saori.inoue@meitetsu-hpt.jp+81-570-023-100

Outcome results